NCT02243397

Brief Summary

The purpose of the study is to investigate the different types and subtypes of cells found in breast tumors. The investigators will do this using a variety of molecular analysis tools that may allow for improved tests. The different types of cells in breast cancer impacts the way individuals respond to various treatments.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
145

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 10, 2014

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

September 15, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 17, 2014

Completed
6.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 19, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 19, 2021

Completed
Last Updated

November 26, 2025

Status Verified

November 1, 2025

Enrollment Period

6.6 years

First QC Date

September 15, 2014

Last Update Submit

November 20, 2025

Conditions

Breast - FemaleBreast - Male

Outcome Measures

Primary Outcomes (1)

  • levels of GM-CSF in plasma

    We will be measuring levels of GM-CSF (Granulocyte-macrophayge colony stimulating factor) from the plasma of the patient before during and after the irradiation treatment to study if there is any increase in the GM-CSF production

    10 years

Eligibility Criteria

Age18 Minutes+
Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

breast cancer patients at Stanford Cancer Center

You may qualify if:

  • Histologically proven diagnosis of breast cancer or a carcinoma of unknown primary consistent with the presentation of a primary breast malignancy.
  • years of age or older.
  • Ability to understand and the willingness to sign a written informed consent do

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford University Cancer Institute

Stanford, California, 94305, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

blood, cerebrospinal fluid, abdominal fluid, chest fluid

Study Officials

  • Kathleen Horst

    Stanford University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Kathleen Horst MD

Study Record Dates

First Submitted

September 15, 2014

First Posted

September 17, 2014

Study Start

September 10, 2014

Primary Completion

April 19, 2021

Study Completion

April 19, 2021

Last Updated

November 26, 2025

Record last verified: 2025-11

Locations

US(1)